Real-World data reveals treatment patterns for advanced prostate cancer
NCT ID NCT07086651
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviewed medical records from over 1,300 men with metastatic prostate cancer that still responds to hormone therapy. Researchers wanted to see how long patients actually take the pills apalutamide or enzalutamide when prescribed by their own doctors in routine care. The goal is to understand real-world treatment patterns, not to test a new drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF THE PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer, Inc
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?